(33) conducted a pivotal Phase II randomized clinical trial to evaluate the efficacy of the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in conjunction with the fluorouracil/leucovorin (FU/LV) regimen for patients diagnosed with metastatic colorectal cancer. This evidence concerns the gene VEGFA and metastatic colorectal cancer.